| abstract |
The invention provides a combined anti-HCMV medicament, each part of the medicament consists of sodium alginate diester, ganciclovir and a solvent, wherein the sodium alginate diester and the ganciclovir are freeze-dried sterilized powder; the solvent is 0.9% sodium chloride injection or 5% glucose sodium chloride injection or normal saline or water for injection, and when the injection is used, the sodium alginate diester and ganciclovir are dissolved by the solvent and prepared into 1mL of injection liquid; the concentration of the alginic sodium diester in the injection is 312.50 mu g/mL-1000.00 mu g/mL, and the concentration of the ganciclovir is 12.50 mu g/mL-63.00 mu g/mL. The invention aims to solve the problem of determining a marine medicament for resisting HCMV (human hepatitis virus) infected liver, which uses the lowest dose in a medicament application range and reduces the toxicity of the medicament as much as possible, wherein the main component is polysaccharide sulphate, and a method for measuring the maximum nontoxic concentration and the minimum effective concentration of the marine medicament. |